Watchlist

Watchlist
Antares Pharma, Inc. (ATRS)
Antares Pharma, Inc. (ATRS)
Biotech Daily Digest For January 16th
It's the fine balance of caffeine and alcohol that bookends my days Tim Minchin While biotech has risen in 2018, its performance YTD lags behind other sectors that will be more immediate beneficiaries of the recently passed tax reform legislation. These include domestica…
Ad Com next week for Clarus Therapeutics' oral testosterone
The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee will meet on Tuesday, January 9 (weather permitting) to discuss Clarus Therapeutics' marketing application seeking approval for JATENZO , an oral softgel capsule containing testosterone undecanoate, a prodrug of testostero…
3 Biotechs For The January Effect
Microcaps and Biotechs may be the perfect formula for portfolio jet fuel in early 2018 If you want to increase your odds of finding alpha in your portfolio performance, you need to look beyond indexing and diversified large caps ( SPY ) ( VOO ) to find special situations where potential rewa…
ATRS Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Antares Pharma, Inc.
Law Offices of Howard G. Smith reminds investors of the December 22, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Antares Pharma, Inc. (Antares or the Company) (NASDAQ: ATRS ) securitie…
Glancy Prongay & Murray Reminds Investors of the December 22, 2017 Deadline in the Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)
Glancy Prongay & Murray LLP (GPM)reminds investors of the December 22, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Antares Pharma, Inc. (Antares or the Company) (NA…
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to Contact the Firm (ATRS)
Glancy Prongay & Murray LLP (GPM)announces that a class action lawsuit has been filed on behalf of investors that purchased Antares Pharma, Inc. (Antares or the Company) (NASDAQ: ATRS ) securities between December 21, 20…
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Antares Pharma, Inc. (NASDAQ:ATRS) securities between December 21, 2…
ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc. (Antares or the Company) (NASDAQ:ATRS) of the December 22, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that ha…
ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc. (Antares or the Company) (NASDAQ:ATRS) of the December 22, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that ha…
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Antares Pharma, Inc. Investors (ATRS)
Glancy Prongay & Murray LLP (GPM) continues its investigation on behalf of Antares Pharma, Inc. (Antares Pharma or the Company) (NASDAQ: ATRS ) investors concerning the Company and its officers possible violations of federal…
Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd Lead Plaintiff Deadline in Securities Class Action Against Antares Pharma, Inc. (ATRS)
Scott+Scott, Attorneys at Law, LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Antares Pharma, Inc. (NASDAQ: ATRS) (Antares or the Company) and…
Antares Pharma, Inc. (ATRS)